Literature DB >> 12939603

Evasive maneuvers by hepatitis C virus.

Brett D Lindenbach1, Charles M Rice.   

Abstract

The hepatitis C virus (HCV) serine protease is necessary for viral replication and represents a valid target for developing new therapies for HCV infection. Potent and selective inhibitors of this enzyme have been identified and shown to inhibit HCV replication in tissue culture. The optimization of these inhibitors for clinical development would greatly benefit from in vitro systems for the identification and the study of resistant variants. We report the use of HCV subgenomic replicons to isolate and characterize mutants resistant to a protease inhibitor. Taking advantage of the replicons' ability to transduce resistance to neomycin, we selected replicons with decreased sensitivity to the inhibitor by culturing the host cells in the presence of the inhibitor and neomycin. The selected replicons replicated to the same extent as those in parental cells. Sequence analysis followed by transfection of replicons containing isolated mutations revealed that resistance was mediated by amino acid substitutions in the protease. These results were confirmed by in vitro experiments with mutant enzymes and by modeling the inhibitor in the three-dimensional structure of the protease.

Entities:  

Year:  2003        PMID: 12939603     DOI: 10.1002/hep.510380327

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

Review 1.  Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.

Authors:  Ali Sabahi; Susan L Uprichard; William C Wimley; Srikanta Dash; Robert F Garry
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

2.  Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

Authors:  Hongmei Mo; Liangjun Lu; Tami Pilot-Matias; Ron Pithawalla; Rubina Mondal; Sherie Masse; Tatyana Dekhtyar; Teresa Ng; Gennadiy Koev; Vincent Stoll; Kent D Stewart; John Pratt; Pam Donner; Todd Rockway; Clarence Maring; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.

Authors:  Meital Gal-Tanamy; Romy Zemel; Larissa Bachmatov; Rohit K Jangra; Assaf Shapira; Rodrigo A Villanueva; Minkyung Yi; Stanley M Lemon; Itai Benhar; Ran Tur-Kaspa
Journal:  Antiviral Res       Date:  2010-08-10       Impact factor: 5.970

Review 4.  Regulation of the Interferon Response by lncRNAs in HCV Infection.

Authors:  Saba Valadkhan; Puri Fortes
Journal:  Front Microbiol       Date:  2018-02-16       Impact factor: 5.640

Review 5.  Running With Scissors: Evolutionary Conflicts Between Viral Proteases and the Host Immune System.

Authors:  Brian V Tsu; Elizabeth J Fay; Katelyn T Nguyen; Miles R Corley; Bindhu Hosuru; Viviana A Dominguez; Matthew D Daugherty
Journal:  Front Immunol       Date:  2021-11-01       Impact factor: 7.561

6.  Exploiting cis-acting replication elements to direct hepatitis C virus-dependent transgene expression.

Authors:  Jing Zhang; Osamu Yamada; Takashi Sakamoto; Hiroshi Yoshida; Hiromasa Araki; Kunitada Shimotohno
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis.

Authors:  Ana M Ortega-Prieto; Julie Sheldon; Ana Grande-Pérez; Héctor Tejero; Josep Gregori; Josep Quer; Juan I Esteban; Esteban Domingo; Celia Perales
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

8.  Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir.

Authors:  Ana I de Ávila; Isabel Gallego; Maria Eugenia Soria; Josep Gregori; Josep Quer; Juan Ignacio Esteban; Charles M Rice; Esteban Domingo; Celia Perales
Journal:  PLoS One       Date:  2016-10-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.